



## Regional Medicines Optimisation Committee

### Medicines Optimisation Prioritisation Panel

Wednesday 16th January 2019, 2.00pm – 4.30pm

### Agenda

Item
Apologies:
Declarations of interest
<b>1. Welcome and Introductions.</b>
<b>2. Minutes of the meeting held on 7th November 2018</b>
<b>3. Review of November 2018 Action Log</b>
<b>4. Feedback from December 2018 MOOG</b>
<b>5. RMOC / PrescQIPP liaison</b>
<b>6. Review of MO topics on-hold / pending</b>
<b>7. Medicines Optimisation Topics submitted:</b> <ul style="list-style-type: none"><li>• Eflornithine for use in transgender patients</li><li>• Formulary application information for biosimilar adalimumab</li><li>• Rivaroxaban 2.5mg for prevention of thrombotic events in CAD or PAD</li><li>• Use of Jorveza for treating active eosinophilic oesophagitis</li><li>• Hydrocortisone granules in capsules for opening (Alkindi)</li><li>• Biosimilar insulin guidance</li><li>• Biosimilar to biosimilar switching</li><li>• Prescribing by Private Providers (to include online GP services)</li><li>• Xonvea - doxylamine succinate and pyridoxine hydrochloride - for information only</li></ul>
<b>Outcome Required:</b> <ul style="list-style-type: none"><li>• <i>Ratification or rejection of Specialist Pharmacy Service recommendation</i></li><li>• <i>Ratified topics prioritised for addition to RMOC work programme</i></li></ul>
<b>Recommendations for further Consideration by the Committee:</b> <ul style="list-style-type: none"><li>• <i>Identification of any further information required before MOPP decision</i></li></ul>



- *Identification of specific questions for each topic to be considered before allocation to RMOC*

**8. New Medicines indications for prioritisation**

**9. AOB**

**Date of the next meeting: Tuesday 5<sup>th</sup> March 2019, 10.00am - 12.00pm**